SUSD2 suppresses CD8 + T cell antitumor immunity by targeting IL-2 receptor signaling.
Bao ZhaoWeipeng GongAnjun MaJianwen ChenMaria VelegrakiHong DongZihao LiuLingling WangTamio OkimotoDevin M JonesYu Leo LeiMeixiao LongKenneth J OestreichQin MaGang XinDavid P CarboneKai HeZihai LiHaitao WenPublished in: Nature immunology (2022)
Dysfunctional CD8 + T cells, which have defective production of antitumor effectors, represent a major mediator of immunosuppression in the tumor microenvironment. Here, we show that SUSD2 is a negative regulator of CD8 + T cell antitumor function. Susd2 -/- effector CD8 + T cells showed enhanced production of antitumor molecules, which consequently blunted tumor growth in multiple syngeneic mouse tumor models. Through a quantitative mass spectrometry assay, we found that SUSD2 interacted with interleukin (IL)-2 receptor α through sushi domain-dependent protein interactions and that this interaction suppressed the binding of IL-2, an essential cytokine for the effector functions of CD8 + T cells, to IL-2 receptor α. SUSD2 was not expressed on regulatory CD4 + T cells and did not affect the inhibitory function of these cells. Adoptive transfer of Susd2 -/- chimeric antigen receptor T cells induced a robust antitumor response in mice, highlighting the potential of SUSD2 as an immunotherapy target for cancer.
Keyphrases
- mass spectrometry
- binding protein
- induced apoptosis
- high resolution
- regulatory t cells
- transcription factor
- type iii
- papillary thyroid
- signaling pathway
- squamous cell carcinoma
- high throughput
- cell therapy
- oxidative stress
- liquid chromatography
- endothelial cells
- high glucose
- endoplasmic reticulum stress
- skeletal muscle
- amino acid
- cell death
- young adults
- bone marrow
- single cell
- cell cycle arrest
- dna binding
- lymph node metastasis
- childhood cancer
- stress induced
- capillary electrophoresis